The strong efficacy and tolerability data increase the probability of success for zovegalisib in vascular anomalies and may drive analyst upgrades. Monitor enrollment updates in expansion cohorts and the ongoing Phase 3 ReDiscover-2 trial in breast cancer for further catalysts.
Price Chart
Executive Summary
Relay Therapeutics reported promising initial Phase 2 data for zovegalisib in PIK3CA-driven vascular anomalies, showing a 60% volumetric response rate across doses and a safety profile supportive of chronic dosing. The data de-risks the asset and expands its potential market beyond breast cancer, supporting continued development.
Key Facts
- 60% volumetric response rate across doses (20 evaluable patients) at 12 weeks with all responses at first MRI.
- 89% of patients showed clinical improvement per investigator assessment (IGIC) and 79% per patient assessment (PGIC) at week 12.
- No patients discontinued due to adverse events; rates of TRAEs and dose modifications were dose-proportional.
- Expansion cohorts opened at 400mg QD and 300mg BID; pediatric dose-finding ongoing.
Financial Impact
No financial figures provided; the data supports zovegalisib's potential in a ~170,000-patient US vascular anomalies market.
Risk Factors
- Early-stage data with small sample size (20 evaluable patients); results may not persist in larger studies.
- Competition from existing PI3K inhibitors (e.g., alpelisib) and other targeted therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $18.66 $18.84 | ▲ +0.96% | ▲ +1.62% | $18.96 (+1.61%) |
Aug 28, 2026 5w ago | Insider Cluster | $18.77 $19.04 | ▼ −1.44% | ▼ −1.33% | $18.96 (−1.01%) |
Aug 18, 2026 6w ago | Insider Cluster | $20.61 $20.57 | ▲ +0.19% | ▼ −0.01% | $18.96 (+8.01%) |
Jul 8, 2026 12w ago | Insider Cluster | $19.63 $19.08 | ▼ −2.80% | ▼ −3.66% | $18.96 (−3.41%) |
Jun 22, 2026 14w ago | 144 | $17.44 $19.74 | ▲ +13.19% | ▲ +12.18% | $18.96 (+8.72%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.81 $15.88 | ▲ +7.22% | ▲ +6.55% | $18.96 (+28.02%) |
May 21, 2026 19w ago | 8-K | $13.53 $14.26 | ▼ −5.40% | ▼ −3.74% | $18.96 (−40.13%) |
May 21, 2026 19w ago | Press Release | $13.66 $14.05 | ▼ −2.86% | ▼ −1.01% | $18.96 (−38.80%) |
May 19, 2026 19w ago | 424B5 | $13.02 $13.90 | ▼ −6.76% | ▼ −4.96% | $18.96 (−45.62%) |
May 19, 2026 19w ago | Press Release | $13.02 $14.43 | ▼ −10.83% | ▼ −9.59% | $18.96 (−45.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access